Search bioRxiv⌕ Search

Biology subjects

Mudgal, R.

Publications and source records attributed to Mudgal, R..

2 recordsLinked to original sources

The specific interface for selenocysteine-decoding tRNA in HIV-1 Gag MAdomain regulates progeny virion infectivity

Localization of HIV-1 particle assembly at the plasma membrane (PM) is mediated by the HIV-1 Gag matrix (MA) domain. Competing binding of PM acidic phospholipids and cellular tRNAs to MA-highly basic region (MA-HBR) likely regulate the PM-specific binding of Gag; however, the specificity of the MA-tRNA interaction and its role in viral replication remain poorly understood. Here, using a modified crosslinking-immunoprecipitation (CLIP)-sequencing workflow for identifying MA-bound tRNAs, we determined that most MA-bound tRNAs were also abundantly present in cells. However, selenocysteine-tRNA (SeCTCA) is overrepresented among Gag-bound tRNAs despite its paucity. The binding of SeCTCA to Gag is entirely dependent on MA-HBR, whereas non-SeCTCA tRNAs can bind Gag through both MA and nucleocapsid domains. Structure prediction of MA-tRNA complexes revealed the binding interface unique to the MA-SeCTCA complex, which was verified experimentally. CLIP experiments demonstrated that this interface is specifically needed for the MA binding to SeCTCA but not to other tRNAs. Notably, disruption of this interface altered Gag localization pattern, reduced infectivity of virions, and impaired virus replication in CD4+ T cells. Collectively, our results indicate that SeCTCA tRNA binds the HIV-1 Gag MA domain with high specificity and promotes virion formation and efficient replication in T cells.

microbiology↗

Selective estrogen receptor modulators limit alphavirus infection by targeting the viral capping enzyme nsP1

Alphaviruses cause animal or human diseases that are characterized by febrile illness, debilitating arthralgia, or encephalitis. Selective estrogen receptor modulators (SERMs), a class of FDA-approved drugs, have been shown to possess antiviral activities against multiple viruses, including Hepatitis C virus, Ebola virus, dengue virus, and vesicular stomatitis virus. Here, we evaluated three SERM compounds, namely 4-hydroxytamoxifen, tamoxifen, and clomifene, for plausible antiviral properties against two medically important alphaviruses, chikungunya virus (CHIKV) and Sindbis virus (SINV). In cell culture settings, these SERMs displayed potent activity against CHIKV and SINV at non-toxic concentrations with EC50 values ranging between 400 nM and 3.9 M. Further studies indicated that these compounds inhibit a post-entry step of the alphavirus life cycle, while enzymatic assays involving purified recombinant proteins confirmed that these SERMs target the enzymatic activity of non-structural protein 1 (nsP1), the capping enzyme of alphaviruses. Finally, tamoxifen treatment restrained CHIKV growth in the infected mice and diminished musculoskeletal pathologies. Combining biochemical, cell culture-based studies, and in vivo analyses, we strongly argue that SERM compounds, or their derivatives, may provide for attractive therapeutic options against alphaviruses.

immunology↗